Becton, Dickinson and Company (NYSE:BDX) Stock Price Target Raised at Citigroup

Becton, Dickinson and Company (NYSE:BDX) had its price objective upped by Citigroup from $208.00 to $241.00 in a research note issued to investors on Friday,Benzinga reports. Citigroup currently has a buy rating on the medical instruments supplier’s stock.

A number of other analysts also recently weighed in on BDX. Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday. TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $190.00 to $225.00 and gave the stock a “sector perform” rating in a research report on Friday. Finally, Wolfe Research initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $193.67.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $1.28 during trading hours on Friday, hitting $212.27. 2,172,550 shares of the company’s stock were exchanged, compared to its average volume of 1,599,485. The company’s 50-day moving average price is $188.17 and its 200-day moving average price is $170.28. Becton, Dickinson and Company has a 1-year low of $137.35 and a 1-year high of $214.88. The stock has a market capitalization of $58.49 billion, a price-to-earnings ratio of 51.27, a PEG ratio of 13.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same period in the previous year, the business posted $3.96 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, sell-side analysts expect that Becton, Dickinson and Company will post 13.24 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be issued a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Thursday, November 5th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,907 shares of company stock valued at $1,269,128 in the last 90 days. 0.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently made changes to their positions in BDX. BankPlus Trust Department raised its position in Becton, Dickinson and Company by 79.6% in the 3rd quarter. BankPlus Trust Department now owns 11,730 shares of the medical instruments supplier’s stock valued at $2,100,000 after purchasing an additional 5,199 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Becton, Dickinson and Company by 24.3% during the third quarter. Aberdeen Group plc now owns 523,400 shares of the medical instruments supplier’s stock worth $93,689,000 after purchasing an additional 102,285 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Becton, Dickinson and Company by 4.6% in the third quarter. Moors & Cabot Inc. now owns 7,158 shares of the medical instruments supplier’s stock valued at $1,281,000 after buying an additional 318 shares in the last quarter. Valmark Advisers Inc. increased its stake in shares of Becton, Dickinson and Company by 20.4% in the third quarter. Valmark Advisers Inc. now owns 3,524 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 596 shares in the last quarter. Finally, Citizens & Northern Corp raised its holdings in shares of Becton, Dickinson and Company by 1.3% in the third quarter. Citizens & Northern Corp now owns 7,883 shares of the medical instruments supplier’s stock valued at $1,411,000 after buying an additional 100 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.